 Hypolipidemic Agents
"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Antilipemic Agents
- Agents, Antilipemic
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in UAMS Profiles by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2016 | 2 | 0 | 2 | | 2012 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2009 | 1 | 1 | 2 | | 2008 | 0 | 1 | 1 | | 2007 | 4 | 1 | 5 | | 2006 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles over the past ten years.
-
Ding Z, Pothineni NVK, Goel A, L?scher TF, Mehta JL. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc Res. 2020 04 01; 116(5):908-915.
-
Kraemer MP, Mao G, Hammill C, Yan B, Li Y, Onono F, Smyth SS, Morris AJ. Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid. J Lipid Res. 2019 11; 60(11):1818-1828.
-
Torok RD, Li JS, Kannankeril PJ, Atz AM, Bishai R, Bolotin E, Breitenstein S, Chen C, Diacovo T, Feltes T, Furlong P, Hanna M, Graham EM, Hsu D, Ivy DD, Murphy D, Kammerman LA, Kearns G, Lawrence J, Lebeaut B, Li D, Male C, McCrindle B, Mugnier P, Newburger JW, Pearson GD, Peiris V, Percival L, Pina M, Portman R, Shaddy R, Stockbridge NL, Temple R, Hill KD. Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. J Am Heart Assoc. 2018 02 10; 7(4).
-
Bader AP, Barone CP, Smeds MR. Risk Factor Modification Behaviors of Practicing Vascular Surgeons. Ann Vasc Surg. 2018 Jan; 46:90-96.
-
Farris RA, Price ET. Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy. Clin Transl Sci. 2017 03; 10(2):110-116.
-
Yadav K, Sharma M, Ferdinand KC. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Nutr Metab Cardiovasc Dis. 2016 10; 26(10):853-62.
-
Takagi M, Sakamoto M, Itoh T, Fujiwara R. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. Drug Metab Pharmacokinet. 2015 Aug; 30(4):288-94.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|